Prostatic Cancer, Castration-Resistant
Information
- Disease name
- Prostatic Cancer, Castration-Resistant
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04381832 | Active, not recruiting | Phase 1/Phase 2 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | July 7, 2020 | August 2024 |
| NCT06276465 | Not yet recruiting | Phase 3 | Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging | July 1, 2024 | July 1, 2032 |
| NCT04141709 | Recruiting | N/A | Local Ablative Radiotherapy for OLIgoprogressive Castration Resistant Prostate Cancer | December 1, 2019 | February 28, 2025 |
| NCT04157088 | Terminated | Phase 2 | Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC) | December 17, 2019 | July 8, 2022 |
| NCT02866916 | Withdrawn | Phase 1 | Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA) | September 2017 | June 2020 |